A randomized controlled clinical trial of Lingzhu Tusizi Pill in the treatment of renal proteinuria

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900024227

Enrollment

Unknown

Registered

2019-07-01

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal albuminuria

Interventions

Chinese medicines group:lingzhu dushizi pill

Comprehensive treatment group:Antipruritic compound for external use combined with western medicine

positive control group:Western medicine oral

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years; 2. The basic disease is primary glomerular disease. 3. The quantitative amount of urine protein was 1.0-3.5g/24h. 4. Patient compliance is good, and voluntary to participate in clinical trials.

Exclusion criteria

Exclusion criteria: 1. Patients with severe primary diseases of heart, brain, liver and hematopoietic system. 2. Blood creatinine >177umol/L. 3. People who are known to be allergic to experimental drugs.

Design outcomes

Primary

Measure	Time frame
creatinine;urea nitrogen;Hemoglobin;hematocrit value;ß2-MG;PTH;CRP;K;CA;P;urine protein quantitation;	—

Countries

China

Contacts

Public ContactHongchun Shen

Southwest Medical University

shenhongchun79@163.com+86 18011020243

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026